Casino Fines Get Inflation Bump: Rule-Breaking Costs More
Published Date: 1/17/2025
Rule
Summary
Starting January 15, 2025, the National Indian Gaming Commission is raising its civil fines to keep up with inflation. Tribes, contractors, and individuals involved in Indian gaming will see penalties go from $63,992 to $65,655 per violation. This yearly update helps keep fines fair and effective at stopping rule-breakers.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Civil penalty raised to $65,655
Starting January 15, 2025, the National Indian Gaming Commission raised the maximum civil fine per violation from $63,992 to $65,655. The Commission applied the OMB cost-of-living multiplier of 1.02598 (based on the October 2024 CPI) to calculate $63,992 × 1.02598 = $65,654.51, rounded to $65,655.
New amount applies to fines assessed after Jan 15, 2025
The new $65,655 penalty applies to civil fines that are assessed after January 15, 2025, even when the underlying violation occurred before that date. That means a violation that happened earlier can be subject to the higher per-violation amount if the penalty is assessed after January 15, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20447, Transparency in Coverage
Starting soon, health plans and insurers must share clearer, easier-to-understand price info for medical services and drugs. This helps you see what in-network and out-of-network costs really look like, with more details and better updates. These changes affect most group and individual health plans and kick in with new reporting rules to make healthcare pricing more transparent and fair.
2026-20469, Privacy Act Exemptions
The Department of the Treasury is creating a new system to handle tips and complaints about waste, fraud, and abuse in federal programs. To keep investigations safe and effective, this system will be partly exempt from some Privacy Act rules starting November 5, 2026. This change helps protect sensitive info while fighting fraud, with no extra costs to the public.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
2026-20448, Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems
Starting October 6, 2026, the FDA is letting certain clinical toxicology test systems skip the usual premarket approval step, cutting red tape and saving money for medical device makers. This change means these devices can get to market faster without extra paperwork, helping labs and patients get quicker results. If you make or sell these test systems, this update is a big win for your business and the healthcare world!
2026-20440, Medical Devices; General and Plastic Surgery Devices; Classification of the Focused Ultrasound System for Non-Thermal, Mechanical Tissue Ablation
The FDA is officially classifying the focused ultrasound system for non-thermal, mechanical tissue ablation as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the device safer and easier to get to patients, boosting innovation and cutting red tape. The new classification is effective October 6, 2026, but has been in effect since October 6, 2023, affecting manufacturers and patients alike.
2026-20443, Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System
The FDA is officially putting high throughput DNA tests for hereditary cancer risk into a safer, easier-to-access category called Class II. This change means these tests will have special rules to keep them safe and effective, while also making it simpler for patients to get these life-saving tools. The new classification took effect on October 6, 2026, helping speed up innovation without extra costs for companies or patients.
Previous / Next Documents
Previous: 2025-01049, Expansion of Buprenorphine Treatment via Telemedicine Encounter
Starting January 17, 2025, doctors can prescribe buprenorphine for opioid treatment through telemedicine, including phone calls without video, after checking patient data. Patients can get up to six months’ worth of medicine split into several prescriptions, making treatment easier and more accessible. Pharmacists must confirm patient identity before filling these prescriptions, helping keep things safe and smooth.
Next: 2025-01062, Inspection Service Authority; Civil Monetary Penalty Inflation Adjustment
Starting January 17, 2025, the Postal Service is raising fines for breaking mail and consumer protection rules to keep up with inflation. This means anyone who messes with mail rules or makes false claims could face bigger penalties. These changes happen every year to make sure fines stay fair and effective.